Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INTERSECT ENT, INC.

(XENT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
26.91(c) 27.05(c) 27.08(c) 27.11(c) 27.05(c) Last
239 332 205 271 199 508 130 732 107 791 Volume
+0.52% +0.52% +0.11% +0.11% -0.22% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 118 M - -
Net income 2021 -69,0 M - -
Net Debt 2021 59,0 M - -
P/E ratio 2021 -12,2x
Yield 2021 -
Sales 2022 144 M - -
Net income 2022 -43,9 M - -
Net Debt 2022 65,0 M - -
P/E ratio 2022 -21,0x
Yield 2022 -
Capitalization 905 M 905 M -
EV / Sales 2021 8,19x
EV / Sales 2022 6,76x
Nbr of Employees 406
Free-Float 93,2%
More Financials
Company
Intersect ENT, Inc. is an ear, nose and throat medical technology provider. Its products are steroid releasing implants designed to treat patients suffering from chronic rhinosinusitis. Its products include the PROPEL family of products PROPEL, PROPEL Mini and PROPEL Contour, and the SINUVA, mometasone furoate Sinus Implant. The PROPEL family of products are used in conjunction with sinus surgery primarily in... 
More about the company
Ratings of Intersect ENT, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about INTERSECT ENT, INC.
11/02INTERSECT ENT : Q3 Earnings Snapshot
AQ
11/02INTERSECT ENT, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
11/02Intersect ENT, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
11/02Intersect ENT Reports Third Quarter 2021 Financial Results - Form 8-K
PU
11/02Earnings Flash (XENT) INTERSECT ENT Reports Q3 Loss $-0.48
MT
11/02Earnings Flash (XENT) INTERSECT ENT Posts Q3 Revenue $24.4M
MT
11/02Intersect ENT Reports Third Quarter 2021 Financial Results
BU
10/28First Implants of PROPEL« Contour in Patients with Chronic Rhinosinusitis Following Fro..
BU
10/08INTERSECT ENT, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
09/27INTERSECT ENT, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Fin..
AQ
09/27Intersect ENT, Inc. Enters into Facility Agreement
CI
09/27INTERSECT ENT : Supplemental Disclosures to the Proxy Statement (Form 8-K)
PU
09/27INTERSECT ENT, INC. : Other Events (form 8-K)
AQ
09/20INTERSECT ENT : Understanding the Difference between COVID-19 Symptoms and Sinus Disease W..
PU
09/17SHAREHOLDER INVESTIGATION : Halper Sadeh LLP Investigates SIC, XENT, INOV, SAFM; Sharehold..
PR
More news
News in other languages on INTERSECT ENT, INC.
11/02Earnings Flash (XENT) INTERSECT ENT affiche un chiffre d'affaires de 24,4 millions de d..
08/06Medtronic va acquérir Intersect ENT pour 1,1 milliard de dollars en espèces, en vue d'a..
08/06La perte nette ajustée d'Intersect ENT au deuxième trimestre diminue alors que les rece..
08/06Earnings Flash (XENT) INTERSECT ENT annonce un chiffre d'affaires de 27,3 millions de d..
07/22Intersect ENT, Inc. réitère ses prévisions de recettes pour l'ensemble de l'année 2021
More news
Analyst Recommendations on INTERSECT ENT, INC.
More recommendations
Chart INTERSECT ENT, INC.
Duration : Period :
Intersect ENT, Inc. Technical Analysis Chart | XENT | US46071F1030 | MarketScreener
Technical analysis trends INTERSECT ENT, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Last Close Price 27,05 $
Average target price 28,25 $
Spread / Average Target 4,44%
EPS Revisions
Managers and Directors
Thomas A. West President, Chief Executive Officer & Director
Richard A. Meier Chief Financial Officer & Executive Vice President
Kieran Thomas Gallahue Chairman
Dana George Mead Independent Director
Cynthia L. Lucchese Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INTERSECT ENT, INC.18.25%905
ABBOTT LABORATORIES20.94%234 157
MEDTRONIC PLC-4.16%150 954
BECTON, DICKINSON AND COMPANY0.06%71 108
HOYA CORPORATION25.65%58 237
DEXCOM, INC.51.03%54 121